Tozorakimab Phase 3 COPD Results: IL-33 Pathway Validation
Review AstraZeneca's tozorakimab Phase 3 MIRANDA trial results for COPD. This analysis explains IL-33 pathway biology and compares itepekimab clinical data.
Back to Articles
Articles tagged with “st2-inhibitors”